ChemoCentryx Inc. (NASDAQ:CCXI) shares were up 3.7% during trading on Thursday . The stock traded as high as $4.83 and last traded at $4.77, with a volume of 155,429 shares changing hands. The stock had previously closed at $4.60.

Several research analysts have commented on CCXI shares. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a report on Wednesday, April 27th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $11.00 price target on shares of ChemoCentryx in a report on Tuesday, August 9th. Finally, Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a report on Thursday, May 19th.

The firm’s 50 day moving average is $4.57 and its 200-day moving average is $3.80. The company’s market cap is $222.57 million.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.